Oceanside, NY, September 19, 2015 --(PR.com
)-- Noted urologic cancer specialist and researcher Michael Herman, M.D., has joined South Nassau Communities Hospital’s medical staff as director of urologic oncology.
“Dr. Herman is in the forefront of the treatment and research of urologic cancers,” said Rajiv Datta, MD, chair of the department of surgery and medical director of the Gertrude & Louis Feil Cancer Center at South Nassau Communities Hospital. “His experience and expertise in using leading-edge medical technologies and therapies to treat urologic cancers, including prostate cancer, will be a benefit to the communities and patients served by South Nassau.”
Prior to coming to South Nassau, Dr. Herman served as Assistant Professor in the Department of Urology at Weill Cornell Medical Center and an Assistant Attending at New York-Presbytherian Hospital. Dr. Herman earned his MD at the University of Texas Southwestern Medical Center and completed his residency at Weill Cornell Medical College. During his residency, Dr. Herman won Physician of the Year, New York-Presbyterian Hospital (2008), First place for AUA/Gyrus Prize Essay Contest (2009), and the Distinguished Housestaff Award, New York-Presbyterian Hospital (2010).
Dr. Herman is a 2015 “New York Super Doctor.” No more than 5% of physicians in the New York metro region achieve this designation, which is given by Key Professional Media, a leading research and medical ranking organization. According to Key Professional Media, in selecting physicians for Super Doctors, the publisher employs a rigorous multi-step process designed to identify physicians who have attained a high degree of peer recognition and professional achievement. Super Doctors is a selective yet diverse listing of outstanding physicians, representing consumer-oriented medical specialties.
Dr. Herman received research support from the National Institutes of Health as a co-investigator exploring the application of multiphoton microscopy in prostate cancer, an advanced imaging technique to improve prostate cancer detection. He also maintains an active presence as a reviewer for multiple top urology journals.
A co-author of three book chapters and more than 30 peer-reviewed journal articles, as well as dozens of abstracts, Dr. Herman continues to be involved in the front line of urologic oncology. His current interests include reducing the over diagnosis and overtreatment of prostate cancer by using the latest biomarkers and imaging techniques. This can reduce the number of unnecessary biopsies while more accurately diagnosing aggressive prostate cancer, thereby leading to improved outcomes for patients. He utilizes novel genetic testing to see who is a good candidate for active surveillance, or monitoring, of their cancers. Finally, he focuses on minimally invasive treatments for prostate, kidney, and bladder cancers, including robotic and laparoscopic surgery. Dr. Herman is interested in facilitating clinical and collaborative research at South Nassau.